From a therapeutic point of view, these results establish the basis for the evaluation of the role of soluble recombinant TRAIL in preventing/attenuating atheromatous progression in CKD patients not undergoing dialysis. The gene discussed is TNFSF10; the disease is chronic kidney disease.